ATRMEDIUM SIGNALFINANCIAL10-K

ATR significantly increased both cash reserves and debt levels while experiencing a decline in operating cash flow generation.

The company appears to have undertaken meaningful financing activities, substantially boosting both its cash position and debt load, which could indicate preparation for acquisitions, capital investments, or strategic initiatives. However, the decline in operating cash flow amid this capital structure adjustment warrants monitoring, as it suggests the core business may be generating less cash while the company is taking on additional leverage.

Comparing 2026-02-06 vs 2025-02-07View on EDGAR →
FINANCIAL ANALYSIS

ATR's balance sheet expanded notably with cash reserves growing substantially to $402.4M and total debt increasing meaningfully to $1.1B, reflecting significant financing activity. Total assets grew 18.5% to $5.3B with current assets up 28.1%, indicating overall business expansion. However, operating cash flow declined 11.4% to $570.0M, creating a mixed picture where balance sheet growth is accompanied by weaker cash generation from operations.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+79.8%
$223.8M$402.4M

Cash position surged 79.8% — strong cash generation or capital raise providing significant financial cushion.

Total Debt
Balance Sheet
+65.6%
$688.1M$1.1B

Debt increased 65.6% — substantial leverage increase; assess whether deployed for growth or covering losses.

Current Assets
Balance Sheet
+28.1%
$1.5B$1.9B

Current assets grew 28.1% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+18.5%
$4.4B$5.3B

Asset base grew 18.5% — expansion through organic growth, acquisitions, or capital deployment.

Inventory
Balance Sheet
+16.5%
$461.8M$537.8M

Inventory built 16.5% — monitor whether demand supports this build or if write-downs may follow.

Operating Cash Flow
Cash Flow
-11.4%
$643.4M$570.0M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-02-06
PRIOR — 2025-02-07
ADDED
The number of outstanding shares of common stock, as of February 2, 2026, was 64,379,735 shares.
Aptar serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care and home care.
Using proprietary design, engineering, materials science, and manufacturing capabilities, Aptar supports customers across these end markets by enabling safe, functional, and differentiated product and service delivery.
Aptar is headquartered in Crystal Lake, Illinois and has approximately 14,000 employees in approximately 20 different countries.
Consumers and patients' preferences for convenience and product differentiation through drug delivery and packaging design and function are important to our customers and have driven a continued shift from non-dispensing formats to dispensing systems that offer enhanced shelf appeal, ease of use, convenience, cleanliness and accuracy of dosage.
A number of our solutions for the beauty, personal care, home care, food and beverage markets are recyclable, reusable or made with recycled content and the Company continues to invest in product platforms designed to improve sustainability, including enhanced recyclability of pharmaceutical delivery systems.
Our primary products are dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions and digital health solutions.
Dispensing pumps are finger-actuated dispensing systems used to dispense sprays, liquids or lotions from non-pressurized containers, ranging from fine-mist pumps for pharmaceutical and fragrance applications, to lotion pumps for more viscous formulations.
Closures include dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
Aerosol valves are used in pressurized containers and include continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications.
REMOVED
The number of outstanding shares of common stock, as of February 3, 2025, was 66,495,293 shares.
Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care, and home care.
Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world.
Aptar is headquartered in Crystal Lake, Illinois and has approximately 13,500 dedicated employees in 20 different countries.
Consumers and patients' preferences for convenience and product differentiation through drug delivery and packaging design and function are important to our customers and they have converted many of their packages from non-dispensing formats to dispensing systems that offer enhanced shelf appeal, ease of use, convenience, cleanliness and accuracy of dosage.
Many of our product solutions for the beauty, personal care, home care, food and beverage markets are recyclable, reusable or made with recycled content and we expect to launch the first fully recyclable pharmaceutical nasal spray.
While we offer a wide variety of services and products, our primary products are dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions and digital health solutions.
Dispensing pumps are finger-actuated dispensing systems that dispense a spray or lotion from non-pressurized containers.
The style of pump used depends largely on the nature of the product being dispensed, from small, fine mist pumps used with pharmaceutical products and perfume, to lotion pumps for more viscous formulas.
Closures are primarily dispensing closures, but to a lesser degree can include non-dispensing closures.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →